Dr. Daniel Carlat is directs Pew's prescription project, which seeks to ensure transparency in physician-industry relationships and promotes policies to reduce or manage conflicts of interest that could affect patient care.
Before joining Pew, Carlat was a practicing psychiatrist and was president and CEO of Carlat Publishing LLC, which publishes non-industry supported continuing medical education newsletters for psychiatrists and other mental health practitioners.
Carlat is the author of numerous peer-reviewed articles and professional books in psychiatry, most notably The Psychiatric Interview: A Practical Guide, currently in its third edition and translated into several languages. In addition to his professional writing, Dr. Carlat has written about conflicts of interest for the New York Times, the New York Times Magazine, and Wired. His article for The New York Times Magazine, "Dr. Drug Rep", was selected for Harper Perennial’s Best Science Writing 2008 anthology.
In 2010, he published his first book for a general audience, Unhinged: A Doctor’s Alarming Revelations about a Profession in Crisis. The book, which proposes solutions for reforming the mental health care system in the U.S., has garnered significant media attention, including a July 2010 interview on NPR’s Fresh Air.
Dr. Carlat received his M.D. at the University of California, San Francisco, and completed his psychiatric residency at Massachusetts General Hospital in Boston. He is associate clinical professor of psychiatry at Tufts School of Medicine.
Recent WorkView All
For all communities, but especially for post-industrial cities such as Philadelphia, increasing the number of residents is necessary to expand the local economy, broaden the tax base to support infrastructure, and draw new employers seeking a skilled workforce. Read More
In 2016, the United States will move significantly closer to a modern, prevention-based food safety system that will reduce foodborne diseases. For the past five years, the U.S. Food and Drug Administration has been implementing the landmark reforms that Congress enacted in the FDA Food Safety Modernization Act (FSMA). This year, FDA staff will continue to finalize regulations and build the... Read More
Recent spikes in the price of certain off-patent medications have caused some legislators and health care professionals to advocate for using compounded drugs—drugs mixed by pharmacies—as a substitute for more expensive, FDA-approved medications. Though well-intentioned, this approach carries significant risks for patients and the sustainability of the drug approval system for the... Read More